News

Chronic Lymphocytic Leukemia After Fludarabine Failure

John Gribben
John Gribben

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as lenalidomide alongside standard fludarabine therapy. At the Paris symposium John Gribben gave Peter Goodwin the latest details.

Download this interview

Similar Interviews

  • Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
  • Susan O’Brien SUSAN O'BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or

  • Audio Journal of Oncology in Advance - March 15th, 2008
  • Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of

  • Audio Journal of Oncology 14.2, March 2006
  • Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 In this edition: It is not necessary to use rituximab along with

    Post a comment